The best indicator for Cintas (CTAS)
We backtested 20 indicators across daily, weekly and hourly charts on real Cintas (CTAS) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 20/50 Cross
On the weekly chart, this is the strongest risk-adjusted edge we found for Cintas (CTAS) over ~43.0 years — trailing buy-and-hold by 5.4% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 20/50 Cross ✓ | Weekly | 12.3% | 0.61 | -74.1% | 44.4% | 18 | -5.4% |
| 2 | WaveTrend (8/6/4) ✓ | Weekly | 8.6% | 0.6 | -45.5% | 78.8% | 33 | -9.1% |
| 3 | Bollinger Mean-Reversion ✓ | Weekly | 6.7% | 0.57 | -18.7% | 92.9% | 28 | -11.0% |
| 4 | CCI ✓ | Weekly | 7.0% | 0.53 | -44.1% | 94.3% | 35 | -10.7% |
| 5 | Stochastic ✓ | Weekly | 6.5% | 0.51 | -44.1% | 84.2% | 38 | -11.2% |
| 6 | ADX / DMI ✓ | Weekly | 7.8% | 0.51 | -67.8% | 50.0% | 54 | -9.9% |
| 7 | RSI Trend (>50) ✓ | Weekly | 8.4% | 0.5 | -80.6% | 44.5% | 110 | -9.3% |
| 8 | Donchian Midline ✓ | Weekly | 8.4% | 0.5 | -68.9% | 48.7% | 115 | -9.3% |
| 9 | Rate of Change ✓ | Weekly | 8.1% | 0.49 | -73.8% | 47.6% | 126 | -9.6% |
| 10 | EMA 50/200 Cross ✓ | Daily | 9.0% | 0.48 | -83.5% | 35.7% | 28 | -8.8% |
| 11 | Holy Grail Confluence ✓ | Daily | 6.4% | 0.48 | -45.1% | 80.4% | 51 | -11.3% |
| 12 | SMA 50/200 Cross ✓ | Daily | 8.6% | 0.47 | -82.7% | 39.3% | 28 | -9.2% |
| 13 | Williams %R ✓ | Weekly | 6.2% | 0.47 | -45.3% | 88.2% | 51 | -11.5% |
| 14 | EMA 20/50 Cross ✓ | Daily | 7.6% | 0.45 | -74.4% | 43.0% | 100 | -10.1% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Cintas (CTAS), EMA 20/50 Cross on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.